A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

Nonparametric Estimation from Incomplete Observations

Edward L. Kaplan, Paul Meier · Journal of the American Statistical Association · 1958 · 38.7K citations

Engineering, Aging, Life Prediction +21

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 2000 · 15.7K citations

World Health Organization, Solid Tumors, Cancer Management +17

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

C. J. Clopper, E. S. Pearson · Biometrika · 1934 · 4.6K citations

Reliability, C. J. Clopper, Statistical Review +11

Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results

Joyce O’Shaughnessy, David Miles, Svetislava J. Vukelja et al. · Journal of Clinical Oncology · 2002 · 1.1K citations

Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

Joanne L. Blum, Stephen E. Jones, Aman U. Buzdar et al. · Journal of Clinical Oncology · 1999 · 787 citations